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Treatment of ruptured abdominal aortic aneurysm
after endovascular abdominal aortic repair: A
comparison with patients without prior treatment
Gioacchino Coppi, MD, Stefano Gennai, MD, Giuseppe Saitta, MD, Roberto Silingardi, MD, and
Sebastiano Tasselli, MD, Modena, Italy
Objective: A retrospective analysis of immediate outcomes following aneurysm rupture (rAAA) in two groups: patients
previously treated at our center with primary endovascular repair (EVAR) and patients without previous EVAR for
abdominal aortic aneurysms (AAA) in an 8-year period.
Methods: Fourteen patients with a confirmed rAAA identified throughout the follow-up period following primary EVAR
repair at our center (from a population of 820 AAA treated at our center in election) were retrospectively compared with
155 patients without previous EVAR in the same time period, from the introduction of an intention-to-treat protocol
with EVAR for rAAA in January 1999. Primary study outcomes included 30-day mortality and severe systemic
complications following rAAA correction with both open and EVAR treatments.
Results: In the 14 patients secondary interventions were necessary throughout follow-up prior to rupture in 43% (6/14).
The mean time to rupture was 50.23 months (9-113). The mean increase in maximum aneurysmal diameter at rupture
was 18.39 mm. Type of endoleaks observed at rupture: 35.7% I proximal, 35.7% III contralateral stump disconnection,
14.3% I distal, 14.3% III midgraft tear: treatment at rupture included five EVAR corrections with aortouniiliac
endografts, four EVAR corrections with extensions, and five surgical conversions. Thirty-day mortality between the two
groups, 28.5% (patients with prior EVAR) 38.7% (patients without prior EVAR), and severe systemic complications, 50%
vs 37.6%, were not found to be statistically significant. Hemodynamic instability, 36% (patients with prior EVAR) 63%
(patients without prior EVAR), was found to be an independent predictor of 30-day mortality (P < .0001), whereas
severe systemic complications, 50% vs 33.5%, did not influence the same outcome (P  .852).
Conclusions: In terms of mortality, it would be logical to expect a protection from the endograft in patients with previous
EVAR. A trend seems to confirm this assumption, but no statistical significance was found, which may be due to the small
population size. ( J Vasc Surg 2009;49:582-8.)Protecting patients with abdominal aortic aneurysms
(AAA) from rupture and aneurysm associated death is the
main goal of endovascular repair (EVAR). The treatment
aims to completely exclude the aneurysmal sac from circu-
lation. The traditional surgical technique dictates the sur-
gical opening of the aneurysmal sac and the replacement of
the arterial wall with a vascular prosthesis, theoretically
avoiding the risk of rupture.1 Comparatively, EVAR has an
incidence of incomplete exclusion throughout the follow-up
period, which in literature ranges from between 6% to 50%
of patients,2 the most frequent reason being caused by
endoleak, what has been termed the “Achilles heel” of
EVAR.3 Graft related endoleaks (type I and III) are associ-
ated with a late risk of rupture, which is assumed but not
proven to be associated with significant pressurization of
the aneurysmatic sac.4
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582Since the introduction of EVAR, complications related
to device failures and endoleaks following EVAR have led
some authors to urge caution in the widespread application
of EVAR.5,6 Recent studies have begun to publish more
advantageous long-term results,7,8 especially associated
with second generation devices, but an undefined durabil-
ity of EVAR still exists.
At rupture, an independent risk factor associated with
immediate mortality is the patients’ hemodynamic sta-
bilty.9 This led us to question that if in the case of rupture,
the presence of an endograft constitutes a protection in
terms of improved hemodynamic stability and therefore
mortality.
METHODS
From January 1999, our center has followed a protocol
for ruptured abdominal aortic aneurysms (rAAA) with an
intention-to-treat with EVAR for all anatomically suitable
patients, excluding young patients (less than 65-years-old).
From January 1999 to December 2007, a total of 169
consecutive patients with rAAA were retrospectively evalu-
ated according to prior primary EVAR for AAA at our
center (14, one patient was subsequently treated for rAAA
at another center) or patients without any prior AAA treat-
ment (155). Patients with acute or symptomatic but intact
aneurysms shown at computed tomography (CT) were
excluded.
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their hemodynamic stability in the period between presen-
tation at hospital through to admittance into the operating
suite; as hemodynamically unstable (defined as unconscious
and/or with a systolic blood pressure constantly less than
80 mm Hg, following fluid resuscitation) or hemodynam-
ically stable (conscious and/or with a systolic blood pres-
sure constantly greater than 80 mm Hg, with or without
fluid resuscitation). All patients were assisted by a vascular
surgeon and an anesthesiologist from their presentation at
emergency through the operating room. Permissive hypo-
tension was practiced with prudent fluid resuscitation to
keep systolic blood pressure around 80 mm Hg. All patients
were assessed by contrast enhanced spiral computed to-
mography (CT) 5 mm slices of the abdomen before enter-
ing the operating suite, apart from those less than 65 years
of age or with severe hypotension (unconscious or with a
systolic blood pressure less than 50 mm Hg, with or with-
out fluid resuscitation), who were transported directly into
the operating suite and assessed for EVAR in the operating
room if a hemodynamic response was achieved with an
occlusion balloon. Rupture with CT was defined as extrav-
asation of blood surrounding the aneurysm as evident by
the scan, and in the cases of patients sent immediately into
the operating room, rupture was confirmed by intraopera-
tive angiography and intravascular ultrasound (IVUS), or
directly during traditional surgery. During the CT scan-
ning, the operating room was prepared, in order to further
reduce delay. In the case of a CT scan, the patients’ ana-
tomic suitability for emergency EVAR was directly deter-
mined by the vascular surgeon from the screen.
Our EVAR procedures have been previously de-
scribed.9 All endografts used in the EVAR correction for
rAAA were commercially available, detailed in Table I. The
endografts were chosen according to the patients’ anatom-
ical characteristics, as interpreted by the vascular surgeon
from the preoperative diagnostic examination.
Open repair was performed in the traditional fashion as
is described in literature.10-12 All grafts used in the study
were commercially available (Table I).
The EVAR follow-up scheme consisted of routine CT
before discharge, at 3 and 12 months and annually there-
after, and echo duplex scanning at 1 and 6 months and
annually thereafter. From January 2007, the annual CT
scan was replaced with an echo duplex scan and a subse-
quent CT scan if required, in order to reduce radiation
exposure and the administration of contrast media, plain
X-ray previous to discharge, at 6 months and annually
thereafter. Open follow-up consisted of an echo duplex
scan at 6 months and annually thereafter.
Data are expressed as mean (range), if continuous, and
as absolute and relative frequency, if categorical. Compar-
isons between continuous variables are performed by
means of t test for unpaired samples, while categorical
variables by means of 2 or Fisher exact test, as appropriate.
Univariate binary logistic regression is used to find out
predictors of 30-day mortality. All two-sided P value .05
are considered statistically significant.RESULTS
A total of 169 patients underwent treatment for rAAA
at our center in an 8-year period from the introduction of
both EVAR and open surgery as treatment options for
rAAA at our center; 155 primary rAAA treatment and 14
treated for rAAA after EVAR.
Patient demographic, comorbidities, and preoperative an-
eurysm anatomical features are displayed in Table II. The two
groups were found to be heterogeneous regarding the inci-
dence of hyperlipidemia (P .022) and obesity (P .036).
Analyzing the follow-up from the initial repair through
to rupture, a rate of 36% of patients (5/14) who had not
followed the correct follow-up protocol was highlighted
(Table III). Six patients (43%) had been treated with
8 secondary interventions prior to rupture; 2 type I proxi-
mal endoleak (Zenith AUI, proximal AneuRx extension
[Medtronic, Minneapolis, Minn]), 1 type I distal endoleak
(Zenith extension), 3 type III contralateral stump discon-
nection (2 Excluder and 1 Passager extensions [Boston
Scientific, Galway, Ireland]), 1 type III midgraft tear (Ex-
cluder extension), and 1 contralateral branch thrombosis
treated with thrombolysis and angioplasty (Table IV).
The mean time between the last consultation and rup-
ture was 21 months. The mean time to rupture from the
primary EVAR repair was 50.23 months, ranging from 9 to
113 months (Table IV).The mean AAA diameter increase
of 18.39 mm with respect to the preoperative measurement
was found to be statistically significant (P  .0001). Inter-
estingly, rupture in five cases was associated with a type I
Table I. Devices and surgical techniques used in the
treatment of rAAA
Variables
rAAA with prior
primary EVAR
rAAA without
prior EVAR
Patients, n 14 155
Endografts,
extensions and
grafts:
Powerlink 1 (1 ext) 4 (2 Bif, 1 AUI, 1
Tube)
Talent 1 (1 AUI) 11 (1 Bif, 10 AUI)
Zenith 5 (4 AUI, 1 exta) 32 (2 Bif, 30 AUI)
Excluder 3 (7 extb) 7 (5 Bif, 2 Tube)
Hemashield Gold — 90
Bard — 11
EVAR conversion –
banding
1 —
Conversion with
bypass
4 —
EVAR, Endovascular repair; rAAA, ruptured abdominal aortic aneurysms;
Bif, bifurcated endograft; AUI, aortouniiliac endograft; Tube, straight tube
endograft; ext, extension.
Powerlink (Endologix Inc, Irvine, Calif); Talent (Medtronic Vascular, Santa
Rosa, Calif); Zenith (Cook Inc., Bloomington, Ind); Excluder (W.L. Gore
and Associates, Flagstaff, Ariz); Hemashield Gold (Boston Scientific, Natick,
Mass); Bard (Bard Inc. Murray Hill, NJ).
aOne patient was treated for a rAAA at primary treatment.
bOne patient was treated with both a Cook and Gore extension.proximal endoleak, of which 80% were stable and 20%
ASA,
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disconnection was evidenced with an inversion of hemody-
namic condition; 20% stable and 80% unstable (Table V).
Ruptured aneurysms were corrected with EVAR in 9
cases (5 with AUI, 4 with endovascular extensions), with
an EVAR conversion in 1 case (surgical banding around
the endograft which was not removed), and 4 patients
were converted to open repair (3 due to the inability to
cannulate the stump through the disconnected limb due to
Table II. Summary of patient demographics, comorbiditi
Variable
rAAA wit
tre
Patients, n
Median age, y (range) 82.97
Sex (M/F) 1
Stability, % (stable/unstable) 6
Comorbidities, %:
Diabetes
Smoker
Hypertension
Hyperlipidemia
Cardiac disease
Carotid disease
Renal disease
Respiratory disease
Previous laparotomy
Obesity
AAA maximum diameter, mm, mean (range) 81.96
Neck diameter, mm, mean (range) 23.64
Neck length, mm, mean (range) 20.73
EVAR, Endovascular repair; rAAA, ruptured abdominal aortic aneurysms;
AUI, aortouniiliac endograft; Tube, straight tube endograft; ext, extension.
Table III. Individual patient details: initial AAA intervent
last check-up prior to rupture, and time to rupture
Pt. No.
Endograft
(year of
primary EVAR)
AAA maximum diameter
preop at initial
EVAR
1 Talent (1999) 80 Susp
CT
2 Vanguard (1997) 73 No
3 Vanguard (1996) 60 Thro
4 Powerlink (2004) 66 No
5a Zenith (2004) 47 Type
6 Talent (2004) 65 No
7 Powerlink (2002) 58 No
8 Stentor (1996) 60 Type
9 Powerlink (2002) 50 No
10 Powerlink (2007) 78 Type
11 Vanguard (1999) 55 No
12 Vanguard (1996) 60 No
13 Vanguard (1997) 55 Type
14 Vanguard (1997) 80 Type
EVAR, Endovascular repair; rAAA, ruptured abdominal aortic aneurysms; A
stump disconnection.
aOriginal diagnosis and treatment for rAAA.
bPatients who had not followed the prescribed follow-up protocol.tortuosity in a type III endoleak and an incomplete sealingwith a proximal extension for a type I proximal endoleak)
(Table IV).
The immediate mortality (within 24 hours) in this
group was 14% (2/14); one patient presented stable and
during traditional surgery fell into a state of instability and
subsequently died for irreversible shock, and one stable
patient treated with EVAR died due to multiorgan failure
(MOF). A further two deaths occurred within 30 days, for
MOF, culminating in a 30-day mortality rate of 28.5%
d preoperative aneurysm anatomical features
r EVAR
t
rAAA without prior EVAR
treatment P value
155
92) 78.57 (53-99) .154
125/30 1.000
37/63 .049
9 .609
35 .146
61 .571
29 .022
46 .763
6 .589
12 .372
30 1.000
11 .660
37 .036
103) 78.23 (60-107) .159
30) 24.92 (17-34) .253
30) 19.92 (0-50) .562
American Society of American Anestheologists; Bif, bifurcated endograft;
etails, significant events throughout follow-up period,
reated complications during
follow-up
(mo, from initial EVAR
intervention)
Time from last
check-up to
rupture (mo)
Time to
rupture
(mo)
endoleak at echo-color Doppler,
sed (84) – untreated
2 61
36b 36
lysis  PTA (6) 68b 74
12 19
tal (12) 15 36
5 14
31b 33
SD (36) 12 93
8 20
ximal (1) 4 9
36b 39
46b 46
ximal (36) 12 79
SD (48, 84) 12 113
bdominal aortic aneurysms; CT, computed tomography; CSD, contralaterales, an
h prio
atmen
14
(65-
2/2
4/36
0
14
71
0
50
7
0
29
14
7
(66-
(19-
(15-ion d
T
ected
refu
mbo
I dis
III C
I pro
I pro
III C
AA, a(Table VI).
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cations, detailed in Table VI.
Comparatively, the treatment of rAAA without prior
EVAR includes 101 patients treated with open surgery and
54 with EVAR. A comparative analysis resulted in a statis-
tically significant difference being found between the he-
modynamic stability of the two groups in favor of those
previously treated with EVAR (P  .049). In the entire
population of rAAA with and without prior EVAR, insta-
bility was found to be a significant predictor of 30-day
mortality (if unstable: odds ratio [OR]  4.77, 95% confi-
dence interval [CI] 2.3-9.9, P  .0001); conversely, the
incidence of systemic complications did not significantly
influence 30-day mortality (in case of complication: OR 
1.07, 95% CI 0.6-2.1, P  .852).
DISCUSSION
The main goal of EVAR for AAA is to prevent rupture
and it is well known that EVAR is not completely effective
in reaching this target.13-16 The Eurostar registry, as
quoted by Szmidt,2 found a cumulative annual risk of
rupture after EVAR of 2% at 6 years; these results were
validated by other studies.2,7,17
The mean time to rupture was into the long term
(50.23 months); two of these cases, however, were evi-
denced at 9 and 14 months (Table III). This study not only
verifies the need for continued long-term surveillance for
Table IV. Follow-up, endoleak, and treatment of rAAA
patients with previous EVAR treatment
Variable
rAAA with
prior EVAR
treatment
Patients, n 14
Follow-up from initial EVAR treatment
through to rAAA:
Patients who hadn’t followed follow-up
protocol, %
36 (5/14)
Patients with secondary interventions, % 43 (6/14)
Time to rupture, mo (range) 50.23 (9-113)
Condition of the aneurysm at rupture:
Endoleak, %:
Type I proximal 35.7 (5/14)
Type I distal 14.3 (2/14)
Type III midgraft tear 14.3 (2/14)
Type III contralateral stump
disconnection
35.7 (5/14)
AAA maximum diameter, mm, mean
(range)
81.96 (66-103)
Average increase in AAA maximum
diameter, mm (range)
18.39 (1-30)
Treatment of rAAA:
EVAR correction with AUI 5
EVAR correction with extensions 4
Conversiona 5
EVAR, Endovascular repair; rAAA, ruptured abdominal aortic aneurysms;
AUI, aortouniiliac endograft.
aOne EVAR conversion, one EVAR correction abandoned due to problems
associated with the introduction of the device.device related complications as often quoted in litera-ture,18-23 but that this surveillance needs to be effective also
in the midterm.
Of the 14 patients with rAAA after EVAR, 43% (6/14)
had been treated with a reintervention throughout the
follow-up prior to rupture (Table III). An average reinter-
vention rate in literature following elective EVAR for AAA
is far less at around 14%.22-24 We have hypothesized two
possible explanations for this discrepancy: (1) previous
attempted correction had been unsuccessful or (2) that the
introduction of catheters and other devices could interrupt
endograft stability, leading to endoleak and eventual rup-
ture. Zarins et al25 in a study of 923 patients treated with
EVAR for AAA, demonstrated that the mean maximum
aneurysm diameter is a significant independent predictor of
rupture, and highlights a percentage of rupture of 3% for
aneurysm diameters from 50 to 59mm compared with 7%
for those greater than 60 mm. This finding is supported in
other studies.7,17,26-30 The average preoperative aneurysm
diameter for the group who subsequently experienced rup-
ture was 63.36 mm, which significantly increased to 81.96
mm (P  .0001). Aneurysm sac changes, however,
throughout follow-up as a prediction of rupture is contro-
versial and often unreliable.19,31 Four patients in this study
had stable or minimal aneurysm sac enlargement (5 mm)
within a year prior to rupture.
In all ruptured aneurysms following EVAR, an en-
doleak was observed. Endoleak represents the most fre-
quent cause of aneurysm rupture after EVAR.3,13 En-
doleaks observed were all type I (50%) and type III (50%),
with no evidence of type II endoleaks (Table III). Type I
and III endoleaks are most commonly associated with
rupture,16,32,33 argued by Hinnen et al4 as being due to a
higher pressurization of the aneurysmatic sac. Further, our
study found an association between type III endoleak and
hemodynamic instability (4/7) compared with type I en-
doleak (1/7) (Table IV). The reason for this is unclear. We
hypothesize that in case of a rupture due to a type I
endoleak, the volume of blood is filtered between the
endograft and the aortic wall into the aneurysmal sac, and at
point of rupture, the blood volume that passes could be
considered less than that which passes at full channel into
the aneurysmatic sac through the endograft’s stump in the
case of a limb disconnection or a large fabric tear. In turn,
the quantity of blood loss affects the patients’ instability,
which is often correlated with poor outcomes.9,21
In light of these findings, in the last 3 years we have
intensified the advised follow-up, above all for patients
who were treated for an aneurysm greater than 60 mm or
who required a reintervention. We have substituted the
annual CT scan to a bi-annual echo duplex scan, with CT
scans requested when more precise imaging is required;
such as in the case of increased sac size 5 mm, en-
doleak, or changes in endograft integrity or suspected
migration. However, we must specify that the biannual
consultations do not completely eliminate the risk of
rupture. Three patients were visited within 6 months
prior to rupture, and only one patient had signs of an
MOF,
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within 3 months.
Instability was found to be a significant predictor of
30-day mortality and was less frequently evidenced in pa-
tients with prior EVAR. From a theoretical point of view,
the presence of the endograft may constitute a type of
Table V. Patients treated for rAAA with previous EVAR c
rAAA with prior EVAR treatm
Variable Total Open EV
Patients, n 14 5 9
Stability %, (Stable/unstable) 64/36 60/40 67/
Immediate mortality, %
(within 24 h)
14 20 11
30 day mortality, % 28.5 40 22
Severe systemic
complications, %
50 40 55
MOF (fatal) — 1 2
Bowel infarction — — —
ACS — 1
Acute renal failure (dialysis) — — —
Stroke — — —
Severe respiratory
insufficiency
— — 1
Gastrointestinal bleeding — — —
Myocardial infarction — 1 1
Creatinine rise 30% — — —
Intestinal ischemia — — —
Digestive hemorrhage — — —
EVAR, Endovascular repair; rAAA, ruptured abdominal aortic aneurysms;
Table VI. Individual patients hemodynamic situation, dia
Pt. No.
Hemodynamic
situation at
presentation Endoleak
1 Stable Type I proximal EVAR
2 Stable Type III CSD Attem
due
intro
Con
3 Stable Type I distal EVAR
4 Stable Type I proximal EVAR
5a Stable Type III midgraft tear EVAR
6 Stable Type I proximal EVAR
7 Stable Type I proximal EVAR
sten
8 Stable Type III CSD EVAR
Gor
9 Stable Type I proximal Conve
10 Unstable Type I distal EVAR
11 Unstable Type III CSD Conve
12 Unstable Type III CSD Conve
13 Unstable Type III midgraft tear EVAR
14 Unstable Type III CSD with
caval fistula
EVAR
EVAR, Endovascular repair; CSD, contralateral stump disconnection; AUI,
IRA, severe respiratory insufficiency; ACS, abdominal compartment syndro
aOriginal diagnosis and treatment for rAAA.protection, reducing bleeding.Obesity and hyperlipidemia were found to be significantly
higher in the group without previous EVAR (P .036, P
.022; Table II). The reason is unclear but could be associated
with findings, which suggest that the incidental identification
of an AAA in obese patients (most often affected by dislipi-
demia) is rendered more complex with the physical impedi-
ared with those treated for rAAA without previous EVAR
rAAA without prior EVAR treatment Statistical
significance
P valueTotal Open EVAR
155 101 54
37.4/62.6 37/64 39/61 .049
27 29.7 22.2 .524
38.7 43.6 29.6 .571
33.5 37.6 26 .216
— 12 1 —
— 8 (6 fatal) —
— 1 3 —
— 4 — —
— 2 (1 minor) 1 —
— 8 4 —
— 1 —
— 2 2 —
— — 3 —
— — 1 —
— — 1 —
multiorgan failure.
is and treatment and postoperative events
eatment at rupture
30-day
mortality
Systemic
complications
(Cook)  Cross over Irreversible
shock
EVAR correction abandoned
oblems associated with the
ion of the device –
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based on blood pressure, which alone is not a sufficient
definition of the gravity of a patient’s condition. However,
in the absence of a precise classification, we adopted the most
commonly used criteria in other studies;35,36 the blood pres-
sure with a cut-off of 80 mm Hg. Further, the low incidence
of rAAA after EVAR renders a statistical significance diffi-
cult to achieve, limiting in turn an effective conclusion to
the study. This study has also made many comparisons with
the EUROSTAR registry, which has been criticized for a
high drop out to follow-up, a factor of particular impor-
tance to a study of rupture after EVAR.
In terms of mortality, it would be logical to expect a
protection from the endograft in patients with previous
EVAR. A trend seems to support this assumption but no
statistical significance was found, which may be due to the
inevitable small population size.
The authors thank Johanna Chester, who assisted in the
coordination of the collection of data, analysis, and writing
of the article.
AUTHOR CONTRIBUTIONS
Conception and design: GC, SG, GS, RS
Analysis and interpretation: GC, SG, GS, ST
Data collection: SG, GS
Writing the article: GC, SG, GS
Critical revision of the article: GC, SG, GS, RS, ST
Final approval of the article: GC, SG, GS, RS, ST
Statistical analysis: SG
Obtained funding: Not applicable
Overall responsibility: GC
REFERENCES
1. Creech O. Endo-aneurysmorrhaphy and treatment of aortic aneurysm.
Ann Surg 1966;164:935-46.
2. Szmidt J, Galazka Z, Rowinski O, Nazarewski S, Jakimowicza T,
Pietrasika K, et al. Late aneurysm rupture after endovascular abdominal
aneurysm repair. Interactive CardioVasc Thoracic Surg 2007;6:490-4.
3. White GH, May J, Waugh RC, Chaufour X, Yu W. Type I and type II
endoleaks: a more useful classification for reporting results of endolu-
minal AAA repair. J Endovasc Surg 1998;5:305-9.
4. Hinnen JW, Koning OHJ, van Bockel JH, Hamming JF. Aneurysm sac
pressure after EVAR: the role of endoleak. Eur J Vasc Endovasc Surg
2007;34:432-41.
5. Ohki T, Veith FJ, Shaw P, Lipsitz E, Suggs WD, Wain RA, et al.
Increasing incidence of midterm and long-term complications after
endovascular graft repair of abdominal aortic aneurysms: a note of
caution based on a 9-year experience. Ann Surg 2001;234:323-34.
6. Collin J, Murie JA. Endovascular treatment of abdominal aortic aneu-
rysm: a failed experiment. Br J Surg 2001;88:1281-2.
7. Brewster DC, Jones JE, Chung TK, Lamuraglia GM, Kwolek CJ,
Watkins MT, et al. Long-term outcomes after endovascular abdominal
aortic aneurysm repair: the first decade. Ann Surg 2006;244:426-38.
8. Feringa HH, Karagiannis S, Vidakovic R, Noordzij PG, Brugts JJ,
Schouten O, et al. Comparison of the incidences of cardiac arrhythmias,
myocardial ischemia, and cardiac events in patients treated with endo-
vascular versus open surgical repair of abdominal aortic aneurysms. Am J
Cardiol 2007;100:1479-84.
9. Coppi G, Silingardi R, Gennai S, Saitta G, Ciardullo AV. A single-center
experience in open and endovascular treatment of hemodynamically
unstable and stable patients with ruptured abdominal aortic aneurysms.
J Vasc Surg 2006;44:1140-7.10. Rutledge R, Oller DW, Meyer AA, Johnson GJ Jr. A statewide,
population-based time-series analysis of the outcome of ruptured ab-
dominal aortic aneurysm. Ann Surg 1996;223:492-502.
11. Dueck AD, Kucey DS, Johnston KW, Alter D, Laupacis A. Survival after
ruptured abdominal aortic aneurysm: effect of patient, surgeon, and
hospital factors. Vasc Surg 2004;39:1253-60.
12. Harris JR, Forbes TL, Steiner SH, Lawlor DK, Derose G, Harris KA.
Risk-adjusted analysis of early mortality after ruptured abdominal aortic
aneurysm repair. J Vasc Surg 2005;42:387-91.
13. Fransen GAJ, Vallabhaneni SR, Van Marrevijk CJ, Laheij RJF, Harris
PL, Buth J, Eurostar. Rupture of infra-renal aortic aneurysm after
endovascular repair: a series from the EUROSTAR registry. Eur J Vasc
Endeovasc Surg 2003;26:487-93.
14. Harris PL, Vallabhaneni SR, Desgranges P, Becquemin J-P, Van Mar-
rewijk C, Laheij RJF. Incidence and risk factor of late rupture, conver-
sion, and death after endovascular repair of infrarenal aortic aneurysms:
the EUROSTAR experience. J Vasc Surg 2000;32:739-49.
15. Hinchliffe RJ, Singh-Ranger R, Davidson IR, Hopkinson BR. Rupture
of an abdominal aortic aneurysm secondary to type II endoleak. Eur J
Vasc Endovasc Surg 2001;22:563-5.
16. Bernhard VM, Mitchell RS, Matsumura JS, Brewster DC, Decker M,
Lamparello P, et al. Ruptured abdominal aortic aneurysm after endo-
vascular repair. J Vasc Surg 2002;35:1155-62.
17. Barnes M, Boult M, Maddern G, Fitridge R. A model to predict
outcomes for endovascular aneurysm repair using preoperative vari-
ables. Eur J Vasc Endovasc Surg 2008:35;571-9.
18. Waasdorp EJ, de Vries JP, Hobo R, Leurs LJ, Buth J, Moll FL, on
behalf of the EUROSTAR Collaborators. Aneurysm diameter and
proximal aortic neck diameter influence clinical outcome of endovascu-
lar abdominal aortic repair: a 4-year EUROSTAR experience. Ann Vasc
Surg 2005;19:755-61.
19. Kubin K, Sodeck GH, Teufelsbauer H, Nowatschka B, Kretschmer G,
Lammer J, et al. Endovascular therapy of ruptured abdominal aneu-
rysm: mid- and long-term results. Cardiovasc Intervent Radiol 2008;
31:496-503.
20. Thomas SM, Beard JD, Ireland M, Ayers S, on behalf of the Vascular
Society of Great Britain and Ireland and the British Society of Interven-
tional Radiology. Results from the prospective registry of endovascular
treatment of abdominal aortic aneurysms (RETA): midterm results to
five years. Eur J Vasc Endovasc Surg 2005;29:563-70.
21. Anain PM, Anain JM Sr, Tiso M, Nader ND, Dosluoglu HH. Early and
midmterm results of ruptured abdominal aortic aneurysms in the endo-
vascular era in a community hospital. J Vasc Surg 2007;46:898-905.
22. Baril DT, Silverberg D, Ellozy SH, Carroccio A, Jacobs TS, Sachdev U,
et al. Endovascular stent-graft repair of failed endovascular abdominal
aortic aneurysm repair. Ann Vasc Surg 2008;22:30-6.
23. Hobo R, Buth J, EUROSTAR collaborators. Secondary interventions
following endovascular abdominal aortic aneurysm repair using current
endografts. A EUROSTAR report. J Vasc Surg 2006;43:896-902.
24. VanBindsbergen L, Dolmans DE, Geenen GP, DeGroot HG, Ho GH,
Vos LD, et al. Endovascular aneurysm repair with Zenith(R) graft.
Complications casued by leg extensions. J Cardiovasc Surg (Torino)
2008;49:311-6
25. Zarins CK, Crabtree T, Bloch DA, Arko FR, Ouriel K, White RA.
Endovascular aneurysm repair at 5 years: does aneurysm diameter
predict outcome? J Vasc Surg 2006;44:920-30.
26. Brewster DC, Cronenwett JL, Hallett JW Jr, Johnston KW, Krupski
WC, Matsumura JS, Joint Council of the American Association for
Vascular Surgery and Society for Vascular Surgery. Guidelines for the
treatment of abdominal aortic aneurysms. Report of a subcommittee of
the Joint Council of the American Association for Vascular Surgery and
Society for Vascular Surgery. J Vasc Surg 2003;37:1106-17.
27. De Rango P, Cao P, Parlani G, Verzini F, Brambilla D. Outcome after
endografting in small and large abdominal aortic aneurysms: a meta-
analysis. Eur J Vasc Endovasc Surg 2008:35;162-72.
28. Peppelenbosch N, Buth J, Harris PL, van Marrewijk C, Fransen G.
Diameter of abdominal aortic aneurysm and outcome of endovascular
aneurysm repair: does size matter? A report from EUROSTAR J Vasc
Surg 2004;39:288-97.
JOURNAL OF VASCULAR SURGERY
March 2009588 Coppi et al29. Ouriel K, Srivastava SD, Sarac TP, O’hara PJ, Lyden SP, Greenberg RK,
et al. Disparate outcome after endovascular treatment of small versus
large abdominal aortic aneurysm. J Vasc Surg 2003;37:1206-12.
30. Leurs LJ HR, Buth J, EUROSTAR Collaborators. The multicenter
experience with a third-generation endovascular device for abdominal
aortic aneurysm repair. A report from the EUROSTAR database. J Car-
diovasc Surg (Torino) 2004;45:293-300.
31. Hinchliffe RJ, Braithwaite BD, Hopkinson BR. The endovascular man-
agement of ruptured abdominal aortic aneurysms. Eur J Vasc Endovasc
Surg 2003;25:191-201.
32. Van Marrewijk CJ, Buth J, Harris PL, Norgren L, Nevelsteen A, Wyatt
MG. Significance of endoleaks after endovascular repair of abdominal
aortic aneurysms: the EUROSTAR experience. J Vasc Surg 2002;35:
461-73.
33. Veith FJ, Baum RA, Ohki T, Amor M, Adiseshiah M, Blankensteijn JD,of opinions expressed at an international conference. J Vasc Surg
2002;35:1029-35.
34. Uppot RN, Sahani DV, Hahn PF, Kalra MK, Saini SS, Mueller PR.
Effect of obesity on image quality: fifteen year longitudinal study for
evaluation of dictated radiology reports. Radiology 2006;240:
435-9.
35. Larzon T, Lindgren R, Norgren L. Endovascular treatment of ruptured
abdominal aortic aneurysms: a shift in paradigm? J Endovasc Ther
2005;12:548-55.
36. Peppelenbosch N, Cuypers PWM, Vahl AC, Vermassen F, Buth J.
Emergency endovascular treatment for ruptured abdominal aortic aneu-
rysm and the risk of spinal cord ischemia. J Vasc Surg 2005;42:608-14.et al. Nature and significance of endoleaks and endotension: summary Submitted Jul 17, 2008; accepted Oct 11, 2008.
